Fennec Pharmaceuticals Inc. (FENC): Operating Income
-$6.28M
Year ended 2025-12-31
-$1.12M
Trailing 12 months to 2026-06-30
| Period ended | Operating Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$6.28M | n/m | 2026-03-27, From 2025-01-01 |
| 2024-12-31 | $2.57M | n/m | 2026-03-27, From 2024-01-01 |
| 2023-12-31 | -$12.77M | n/m | 2025-03-26, From 2023-01-01 |
| 2022-12-31 | -$22.59M | n/m | 2024-03-29, From 2022-01-01 |
| 2021-12-31 | -$17.22M | n/m | 2023-03-29, From 2021-01-01 |
| 2020-12-31 | -$17.89M | n/m | 2022-02-28, From 2020-01-01 |
| 2019-12-31 | -$13.01M | n/m | 2021-03-30, From 2019-01-01 |
| 2018-12-31 | -$10.41M | n/m | 2020-02-14, From 2018-01-01 |
| 2017-12-31 | -$6.95M | n/m | 2019-03-15, From 2017-01-01 |
| 2016-12-31 | -$2.87M | n/m | 2018-03-28, From 2016-01-01 |
| 2015-12-31 | -$1.89M | n/m | 2017-03-29, From 2015-01-01 |
| 2014-12-31 | -$2.88M | n/m | 2016-03-28, From 2014-01-01 |
| 2013-12-31 | -$1.93M | n/m | 2015-03-31, From 2013-01-01 |
| 2012-12-31 | -$3.62M | n/m | 2014-03-31, From 2012-01-01 |
| 2011-12-31 | -$3.44M | n/m | 2013-04-01, From 2011-01-01 |
| 2010-12-31 | -$4.60M | n/a | 2012-03-27, From 2010-01-01 |
Operating Income at similar companies
| Company | Year ended | Operating Income | Change YoY |
|---|---|---|---|
| Fennec Pharmaceuticals Inc. (FENC) | 2025-12-31 | -$6.28M | n/m |
| Editas Medicine, Inc. (EDIT) | 2025-12-31 | -$160.01M | n/m |
| Voyager Therapeutics, Inc. (VYGR) | 2025-12-31 | -$131.84M | n/m |
| Sangamo Therapeutics, Inc (SGMOQ) | 2025-12-31 | -$121.24M | n/m |
| Kymera Therapeutics, Inc. (KYMR) | 2025-12-31 | -$349.40M | n/m |
| Protalix BioTherapeutics, Inc. (PLX) | 2025-12-31 | -$5.50M | n/m |
| Invivyd, Inc. (IVVD) | 2025-12-31 | -$55.56M | n/m |
| C4 Therapeutics, Inc. (CCCC) | 2025-12-31 | -$115.22M | n/m |
| X4 Pharmaceuticals, Inc (XFOR) | 2025-12-31 | -$86.88M | n/m |
Compare FENC, EDIT, VYGR, SGMOQ side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗